OriGen Biomedical
OriGen Biomedical is a privately held Austin, Texas-based medical device manufacturer that designs and sells ISO 13485-certified cryopreservation bags, cell culture bags, DMSO solutions, and closed-system fluid transfer accessories for cell and gene therapy labs, cord blood banks, biobanks, tissue banks, and transfusion medicine customers worldwide.
- Company typePrivate
- Founded2005
- HeadquartersAustin, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What OriGen Biomedical does
OriGen Biomedical, Inc. is a privately held specialty medical device manufacturer founded in 2005 and headquartered in Austin, Texas, that designs and produces single-use cryopreservation and cell culture consumables for the cell and gene therapy, cord blood, biobanking, tissue banking, and transfusion medicine markets. Its core product platform centers on EVA-film freezing bags (CryoStore family including standard, 25mL, Conical, and FLEX variants) qualified for cryogenic use down to -196°C, supplemented by PermaLife and Evolve cell culture bags, the TissueVault tissue freezing bag, CryoPur 100% DMSO and CryoPur-D buffered cryopreservation solutions, and an accessory ecosystem including the Cell Connect closed-system fluid transfer device, spike adapters, manifold sets, syringe sets, the VSV Needle-Free Vial Spike, and the Tube Sealer CR6. All products are manufactured under ISO 13485:2016 and MDSAP quality systems with FDA 510(k) clearance and CE marking on key devices, and validation includes bioburden, endotoxin, gamma sterilization resistance, and ISO 10993 biocompatibility testing.
The company generates revenue through quote-based, multi-year contract sales of hardware consumables, distributed via a hybrid model of direct sales in the United States, Canada, and the United Kingdom and a global distributor network with European fulfillment from a Netherlands warehouse. GTM is sales-led, supplemented by an active conference circuit (ASGCT, ISCT, Advanced Therapies Week, EBMT, AABB, SITC), content marketing through a News & Insights blog and quarterly newsletter, and a client dashboard portal for IFUs, certificates of conformance, white papers, and validation summaries. Beth San Segundo serves as President and CEO; the company is independently and likely founder-owned, with no disclosed external private equity or venture capital backing and no public funding rounds on record.
OriGen Biomedical firmographics
Firmographics- Name
- OriGen Biomedical
- Legal name
- OriGen Biomedical, Inc.
- Website
- https://origen.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- OriGen Biomedical is a privately held Austin, Texas-based medical device manufacturer that designs and sells ISO 13485-certified cryopreservation bags, cell culture bags, DMSO solutions, and closed-system fluid transfer accessories for cell and gene therapy labs, cord blood banks, biobanks, tissue banks, and transfusion medicine customers worldwide.
- Ownership category
- akta.pro rank
OriGen Biomedical industry classification
Industry- Product category
- Cryopreservation Medical Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies (HLAAAJAN)
- akta.pro secondary industries
- Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats) (HLAGAIAJ), Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low) (HLAGAGAK)
Keywords
Where OriGen Biomedical is headquartered
LocationHeadquarters
- HQ city
- Austin
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
OriGen Biomedical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Product Sales: OriGen Biomedical generates revenue through the sale of cryopreservation and cell culture medical devices including CryoStore Freezing Bags, Cell Connect Accessories, CryoPur DMSO Solutions, PermaLife Cell Culture Bags, Evolve Cell Culture Bags, TissueVault Tissue Freezing Bags, and accessory sets. Products are sold directly to customers in US, Canada, and UK, and through global distributors in other regions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based pricing for all products |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
OriGen Biomedical product offering
Product offeringCore offering
OriGen Biomedical manufactures and sells single-use medical devices for cryopreservation, cell culture, and solid tissue preservation, including the CryoStore family of EVA film freezing bags qualified for cryogenic temperatures down to -196°C. Its portfolio also spans closed-system fluid transfer accessories such as the Cell Connect, cell culture bags (PermaLife and Evolve), the TissueVault tissue freezing bag, and CryoPur 100% DMSO and CryoPur-D buffered cryopreservation solutions. Products are produced under ISO 13485 and MDSAP quality systems with FDA 510(k) clearance and CE marking on key lines.
Product overview
OriGen Biomedical offers a unified portfolio of single-use medical devices for cryopreservation, cell culture, and solid tissue preservation. The core product lines include CryoStore Freezing Bags (available in standard, 25mL, Conical, and FLEX variants) and PermaLife/Evolve Cell Culture Bags, which serve as the primary containment platforms. These are complemented by supporting solutions including CryoPur DMSO products (CryoPur 100% and CryoPur-D buffered formula), the TissueVault tissue freezing bag for solid specimens, and accessory products including the Cell Connect Accessory for closed-system processing, Spike Adapters, Manifold Sets, VSV Needle-Free Vial Spike, and Tube Sealer. The product ecosystem is designed for cell therapy, biobanking, transfusion medicine, and regenerative medicine applications, with all products manufactured under ISO 13485 and GMP standards.
Differentiator
Problem solved
Functional benefit
Brands
- CryoStore: Cryopreservation freezing bags including CryoStore Freezing Bag, CryoStore 25, CryoStore Conical, and CryoStore FLEX variants.
- PermaLife
- O-Wrap
- CryoPur
- TissueVault
- Cell Connect
Products and services
- CryoStore Freezing Bag FDA 510(k)-cleared and CE-marked EVA-film freezing bag for cryogenic storage of blood components and cell products, validated for use down to -196°C in liquid nitrogen environments.
- CryoStore 25 Freezing Bag Compact freezing bag variant designed for smaller-volume cryogenic storage applications within the CryoStore family.
- CryoStore Conical Freezing Bag Conical-shaped freezing bag designed for specific cryopreservation workflows and sample handling requirements.
- CryoStore FLEX Bag Flexible-configuration freezing bag offering adaptable tubing and port options for various cryogenic storage applications.
- O-Wrap Overwrap Bag Secondary containment bag designed to contain and protect freezing bags during long-term liquid nitrogen storage.
- Tube Sealer CR6 Device for heat-sealing tubing in cryopreservation workflows to maintain closed-system integrity.
- PermaLife Cell Culture Bag Cell culture bag indicated for use in protecting, storing, and freezing cells and tissues.
- Evolve Cell Culture Bag Cell culture bag designed for cell culture applications with features supporting cell growth and handling.
- TissueVault Cell and Tissue Freezing Bag Specialized freezing bag indicated for freezing solid tissues and specimens at any temperature including direct immersion in liquid nitrogen.
- CryoPur 100% DMSO Solution Pharmaceutical-grade dimethyl sulfoxide solution indicated for preservation of stem cells and blood components in a frozen state. For Research Use Only in the United States, Africa, Australia, and Asia.
- CryoPur-D Buffered DMSO Solution Buffered DMSO solution combining 55% DMSO with 5% Dextran-40 for enhanced cryopreservation of stem cells and blood components.
- Cell Connect Accessory Single-use fluid-transfer accessory that connects multiple cell sources and freezing media to up to four CryoStore Freezing Bags simultaneously, available in CC1 and CC2 configurations with SCD-weldable PVC tubing and needle-free valve design for closed-system processing.
- Manifold Sets Multi-port fluid transfer sets for connecting multiple containers in cell processing workflows.
- Spike Adapters Accessory components for fluid transfer connections in cryopreservation and cell culture workflows.
Quantifiable outcome
- Products validated for cryogenic use down to -196°C with no evidence of cracks, leaks, or material degradation under tested conditions including thermal shock, long-term freezing, and repeated freeze-thaw cycles
- +1 more outcomes
Companies that use OriGen Biomedical
Customer profileNamed customers7 records
Segments5 records
Ideal customer profiles5 records
OriGen Biomedical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
OriGen Biomedical partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- Austin Chamber of CommerceminorOriGen Biomedical became a member of the Austin Chamber of Commerce in June 2026. This membership supports local business networking and community engagement in the company's headquarters region.
- American Society of Gene & Cell Therapy (ASGCT)coreOriGen Biomedical participates in the ASGCT Annual Meeting, the primary professional membership organization for gene and cell therapy. The company maintains a booth presence (Booth 417 for 2027) at this major industry conference.
- Phacilitate (Advanced Therapies Week)coreOriGen Biomedical participates in Advanced Therapies Week, celebrating 22 years of advancing biotech innovation. This event brings together the global cell and gene therapy (CGT) community and provides a venue for knowledge sharing, strategic partnerships, and showcasing innovations.
- Blood Cancer UnitedcoreOriGen Biomedical partners with Blood Cancer United's Light The Night campaign, a movement dedicated to bringing hope to patients and families affected by blood cancers. Three employees serve on the 2026 Austin Light The Night Leadership Committee. The partnership aligns with OriGen's vision to support transformational therapies and cell and gene therapy advancement.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
OriGen Biomedical competitors and assessment
Company assessmentDirect peers
- Cryoport Systems: Provider of cryogenic logistics, biostorage, and temperature-controlled supply chain solutions for the life sciences industry. Comparable to OriGen in serving cell therapy and biobank end-markets with complementary cryopreservation infrastructure.
- BioLife Solutions: Public biopreservation specialist offering CryoStor and other DMSO/cryopreservation media, plus storage and shipping tools. Direct competitor to OriGen's CryoPur DMSO solutions and CryoStore bag line in cell therapy manufacturing workflows.
- STEMCELL Technologies: Specialty supplier of cell culture media, cryopreservation reagents (e.g., CryoStor competitor products), and tools for stem cell and immunology research. Closely comparable niche focus and customer overlap with OriGen.
Broad incumbents
- Miltenyi Biotec: Cell therapy solutions provider offering instruments, reagents, and consumables for cell processing, including closed-system workflows comparable to OriGen's Cell Connect and CryoStore products.
- Avantor: Global lab supplies and bioproduction distributor/manufacturer with cryopreservation and bioprocessing consumables sold through broad catalog channels. Competes with OriGen via catalog reach and bundled procurement programs.
- Cytiva (Danaher): Large-scale bioprocessing and cell therapy supplier offering cell culture media, single-use systems, and cryopreservation-adjacent products. Competes with OriGen at large cell therapy manufacturers seeking consolidated vendor relationships.
- Lonza: Global contract development and biomanufacturing organization with cell and gene therapy services and supporting consumables. Overlaps with OriGen at cell therapy manufacturers via combined services and supply offerings.
- Thermo Fisher Scientific: Diversified life sciences tools and bioproduction supplier with cryopreservation products (e.g., Nunc, Gibco cell culture and cryogenic storage offerings). Overlaps with OriGen across biobanking, cell therapy, and general lab consumables.
- Sartorius: Global bioprocessing incumbent supplying cell therapy manufacturers with a broad portfolio of single-use bags, fluid management, and bioprocessing platforms. Competes with OriGen in cell therapy consumables via broader integrated offerings.
Emerging players
- CellGenix: Supplier of raw materials and cryopreservation media (e.g., CryoMACS, DMSO-based solutions) for cell and gene therapy manufacturing. Direct overlap with OriGen's CryoPur DMSO line in regulated cell therapy workflows.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
OriGen Biomedical compliance and trust
Trust signalCompliance3 records
OriGen Biomedical financial estimates
Financial estimateRevenue estimate
Valuation estimate
OriGen Biomedical leadership team
Management profileNumber of profiles
Profiles4 records
OriGen Biomedical funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OriGen Biomedical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OriGen Biomedical
What does OriGen Biomedical do?
OriGen Biomedical manufactures and sells single-use medical devices for cryopreservation, cell culture, and solid tissue preservation, including the CryoStore family of EVA film freezing bags qualified for cryogenic temperatures down to -196°C. Its portfolio also spans closed-system fluid transfer accessories such as the Cell Connect, cell culture bags (PermaLife and Evolve), the TissueVault tissue freezing bag, and CryoPur 100% DMSO and CryoPur-D buffered cryopreservation solutions. Products are produced under ISO 13485 and MDSAP quality systems with FDA 510(k) clearance and CE marking on key lines.
Is OriGen Biomedical a public or private company?
OriGen Biomedical is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was OriGen Biomedical founded?
OriGen Biomedical was founded in 2005. It employs 101 to 250 people.
Where is OriGen Biomedical based?
OriGen Biomedical is headquartered in Austin, United States, in the North America region.
How does OriGen Biomedical make money?
One revenue line is on record: medical Device Product Sales.
Who are OriGen Biomedical's main competitors?
Direct peers on record are Cryoport Systems, BioLife Solutions and STEMCELL Technologies. Broad incumbents are Miltenyi Biotec, Avantor, Cytiva (Danaher), Lonza, Thermo Fisher Scientific and Sartorius. CellGenix is listed as an emerging player.
Does OriGen Biomedical have an API?
No public API is recorded for OriGen Biomedical.
What industry is OriGen Biomedical in?
OriGen Biomedical's product category is Cryopreservation Medical Devices. Its primary akta.pro industry code is HLAAAJAN, Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies, with a secondary code of HLAGAIAJ, Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats). Its NAICS code is 3391 and its SIC code is 3841.